• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对由PIKA佐剂的S三聚体新冠疫苗的快速且持久的免疫反应。

Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.

作者信息

Liu Yuan, Dai Lianpan, Feng Xiaoli, Gao Ran, Zhang Nan, Wang Bin, Han Jianbao, Zou Qingcui, Guo Xiling, Zhu Hua, Liu Jiangning, Qin Chuan, Zhang Yi, Bao Linlin, Li Minghua

机构信息

YishengBio Co., Ltd, Beijing, China.

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

出版信息

Mol Biomed. 2021;2(1):29. doi: 10.1186/s43556-021-00054-z. Epub 2021 Sep 27.

DOI:10.1186/s43556-021-00054-z
PMID:34766005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8475395/
Abstract

UNLABELLED

In the face of the emerging variants of SARS-CoV-2, there is an urgent need to develop a vaccine that can induce fast, effective, long-lasting and broad protective immunity against SARS-CoV-2. Here, we developed a trimeric SARS-CoV-2 S protein vaccine candidate adjuvanted by PIKA, which can induce robust cellular and humoral immune responses. The results showed a high level of neutralizing antibodies induced by the vaccine was maintained for at least 400 days. In the study of non-human primates, PIKA adjuvanted S-trimer induced high SARS-CoV-2 neutralization titers and protected from virus replication in the lung following SARS-CoV-2 challenge. In addition, the long-term neutralizing antibody response induced by S-trimer vaccine adjuvanted by PIKA could neutralize multiple SARS-CoV-2 variants and there is no obvious different among the SARS- CoV-2 variants of interest or concern, including B.1.351, B.1.1.7, P.1, B.1.617.1 and B.1.617.2 variants. These data support the utility of S-trimer protein adjuvanted by PIKA as a potential vaccine candidate against SARS-CoV-2 infection.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1186/s43556-021-00054-z.

摘要

未标注

面对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）出现的变种，迫切需要研发一种能够诱导针对SARS-CoV-2快速、有效、持久且广泛保护性免疫的疫苗。在此，我们研发了一种由PIKA佐剂的三聚体SARS-CoV-2 S蛋白候选疫苗，其能够诱导强烈的细胞免疫和体液免疫反应。结果显示，该疫苗诱导产生的高水平中和抗体至少维持了400天。在非人灵长类动物研究中，PIKA佐剂的S三聚体诱导出高SARS-CoV-2中和滴度，并在SARS-CoV-2攻击后保护肺部免受病毒复制。此外，PIKA佐剂的S三聚体疫苗诱导的长期中和抗体反应能够中和多种SARS-CoV-2变种，并且在感兴趣或关注的SARS-CoV-2变种之间没有明显差异，包括B.1.351、B.1.1.7、P.1、B.1.617.1和B.1.617.2变种。这些数据支持了PIKA佐剂的S三聚体蛋白作为一种针对SARS-CoV-2感染的潜在候选疫苗的效用。

补充信息

在线版本包含可在10.1186/s43556-021-00054-z获取的补充材料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/96ad11056e8b/43556_2021_54_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/40b73ec5ec4c/43556_2021_54_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/034a49050c13/43556_2021_54_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/78af412284b8/43556_2021_54_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/139228ef3807/43556_2021_54_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/96ad11056e8b/43556_2021_54_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/40b73ec5ec4c/43556_2021_54_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/034a49050c13/43556_2021_54_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/78af412284b8/43556_2021_54_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/139228ef3807/43556_2021_54_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c091/8607388/96ad11056e8b/43556_2021_54_Fig5_HTML.jpg

相似文献

1
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.对由PIKA佐剂的S三聚体新冠疫苗的快速且持久的免疫反应。
Mol Biomed. 2021;2(1):29. doi: 10.1186/s43556-021-00054-z. Epub 2021 Sep 27.
2
A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates.三聚体形式的重组受体结合结构域可在非人灵长类动物中产生针对SARS-CoV-2感染的保护性免疫。
Innovation (Camb). 2021 Aug 28;2(3):100140. doi: 10.1016/j.xinn.2021.100140. Epub 2021 Jun 19.
3
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.含乳化佐剂的低剂量 SARS-CoV-2 S 三聚体诱导 Th1 偏向的保护性免疫。
Int J Mol Sci. 2022 Apr 28;23(9):4902. doi: 10.3390/ijms23094902.
4
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
5
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.佐剂 SARS-CoV-2 受体结合域纳米颗粒疫苗在猕猴中的有效性和广度
bioRxiv. 2021 Apr 10:2021.04.09.439166. doi: 10.1101/2021.04.09.439166.
6
Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.单次免疫表达刺突蛋白和核衣壳蛋白的重组 ACAM2000 痘苗病毒可保护仓鼠免受 SARS-CoV-2 引起的临床疾病。
J Virol. 2022 May 11;96(9):e0038922. doi: 10.1128/jvi.00389-22. Epub 2022 Apr 12.
7
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.一种基于人体细胞的 SARS-CoV-2 疫苗可引发强烈的中和抗体反应，并可保护小鼠免受 SARS-CoV-2 攻击。
Emerg Microbes Infect. 2021 Dec;10(1):1555-1573. doi: 10.1080/22221751.2021.1957400.
8
Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.基于 CHO 生产的、预融合 Spike 三聚体和铝佐剂/CpG 佐剂的重组 COVID-19 疫苗的开发。
Vaccine. 2021 Nov 26;39(48):7001-7011. doi: 10.1016/j.vaccine.2021.10.066. Epub 2021 Oct 30.
9
Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants.经鼻腔给予重组 RBD 疫苗可诱导针对包含奥密克戎的 SARS-CoV-2 变异株的长期免疫。
Signal Transduct Target Ther. 2022 May 17;7(1):159. doi: 10.1038/s41392-022-01002-1.
10
Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.疫苗诱导的针对 SARS-CoV-2 病毒变异株的全身和黏膜 T 细胞免疫。
Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2118312119. doi: 10.1073/pnas.2118312119. Epub 2022 May 13.

引用本文的文献

1
Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen.中东呼吸综合征冠状病毒预融合刺突三聚体寡聚体作为疫苗免疫原的鉴定和免疫原性评估。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2351664. doi: 10.1080/21645515.2024.2351664. Epub 2024 May 17.
2
IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant.用PIKA佐剂的重组三聚体SARS-CoV-2刺突蛋白诱导的IgG1主导的抗体反应。
Vaccines (Basel). 2023 Apr 11;11(4):827. doi: 10.3390/vaccines11040827.
3
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress.

本文引用的文献

1
Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel.BNT162b2疫苗接种后传染性降低：以色列的一项前瞻性队列研究。
Lancet Reg Health Eur. 2021 Aug;7:100150. doi: 10.1016/j.lanepe.2021.100150. Epub 2021 Jul 7.
2
SARS-CoV-2 variants, spike mutations and immune escape.SARS-CoV-2 变体、刺突突变和免疫逃逸。
Nat Rev Microbiol. 2021 Jul;19(7):409-424. doi: 10.1038/s41579-021-00573-0. Epub 2021 Jun 1.
3
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
针对人类贝塔冠状病毒的重组蛋白疫苗：策略、方法和进展。
Int J Mol Sci. 2023 Jan 15;24(2):1701. doi: 10.3390/ijms24021701.
4
SARS-CoV-2 spike trimer vaccine expressed in Nicotiana benthamiana adjuvanted with Alum elicits protective immune responses in mice.烟草原生质体表达的 SARS-CoV-2 刺突三聚体疫苗与 Alum 佐剂联合使用可在小鼠中引发保护性免疫应答。
Plant Biotechnol J. 2022 Dec;20(12):2298-2312. doi: 10.1111/pbi.13908. Epub 2022 Sep 5.
5
Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019.Toll样受体信号通路在严重急性呼吸综合征冠状病毒2诱导的固有免疫反应中的作用以及Toll样受体免疫调节剂在2019冠状病毒病患者中的潜在应用价值
Front Microbiol. 2022 Jun 27;13:948770. doi: 10.3389/fmicb.2022.948770. eCollection 2022.
6
Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases.基于Toll样受体激动剂的传染病疫苗佐剂研发的最新进展
Pharmaceutics. 2022 Feb 16;14(2):423. doi: 10.3390/pharmaceutics14020423.
低剂量候选疟疾疫苗 R21 联合 Matrix-M 佐剂，季节性接种在布基纳法索儿童中的效果：一项随机对照试验。
Lancet. 2021 May 15;397(10287):1809-1818. doi: 10.1016/S0140-6736(21)00943-0. Epub 2021 May 5.
4
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.NVX-CoV2373 新冠疫苗对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.
5
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白E484K突变降低抗体中和作用。
Lancet Microbe. 2021 Jul;2(7):e283-e284. doi: 10.1016/S2666-5247(21)00068-9. Epub 2021 Apr 7.
6
Emerging concepts in the science of vaccine adjuvants.疫苗佐剂科学中的新观点。
Nat Rev Drug Discov. 2021 Jun;20(6):454-475. doi: 10.1038/s41573-021-00163-y. Epub 2021 Apr 6.
7
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.新冠病毒mRNA-1273疫苗第二剂接种后6个月的抗体持久性
N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6.
8
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
9
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.多种 SARS-CoV-2 变异株逃避疫苗诱导的体液免疫中和作用。
Cell. 2021 Apr 29;184(9):2372-2383.e9. doi: 10.1016/j.cell.2021.03.013. Epub 2021 Mar 12.
10
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.